Literature DB >> 10597268

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway.

X Fang1, S Yu, A Eder, M Mao, R C Bast, D Boyd, G B Mills.   

Abstract

The function of the pro-apoptotic molecule BAD is regulated by phosphorylation of two sites, serine-112 (Ser-112) and serine-136 (Ser-136). Phosphorylation at either site results in loss of the ability of BAD to heterodimerize with the survival proteins BCL-XL or BCL-2. Phosphorylated BAD binds to 14-3-3 and is sequestered in the cytoplasm. It has been shown that phosphorylation of BAD at Ser-136 is mediated by the serine/threonine protein kinase Akt-1/PKB which is downstream of phosphatidylinositol 3-kinase (PI3K). The signaling process leading to phophorylation of BAD at Ser-112 has not been identified. In this study, we show that phosphorylation of the two serine residues of BAD is differentially regulated. While Ser-136 phosphorylation is concordant with activation of Akt, Ser-112 phosphorylation does not correlate with Akt activation. Instead, we demonstrate that activated Ras and Raf, which are upstream of mitogen-activated protein kinases (MAPK), stimulate selective phosphorylation of BAD at Ser-112. Furthermore, phosphorylation of Ser-112, but not Ser-136 requires activation of the MAPK pathway as the MEK inhibitor, PD 98059, blocks EGF-, as well as activated Ras- or Raf-mediated phosphorylation of BAD at Ser-112. Therefore, the PI3K-Akt and Ras-MAPK pathways converge at BAD by mediating phosphorylation of distinct serine residues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597268     DOI: 10.1038/sj.onc.1203076

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  94 in total

1.  Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A.

Authors:  X Fang; S X Yu; Y Lu; R C Bast; J R Woodgett; G B Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 2.  Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis.

Authors:  M P Scheid; J R Woodgett
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

3.  ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice.

Authors:  J L Smith; A E Schaffner; J K Hofmeister; M Hartman; G Wei; D Forsthoefel; D A Hume; M C Ostrowski
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 4.  Functional specificity in 14-3-3 isoform interactions through dimer formation and phosphorylation. Chromosome location of mammalian isoforms and variants.

Authors:  Alastair Aitken
Journal:  Plant Mol Biol       Date:  2002-12       Impact factor: 4.076

5.  HK2 Recruitment to Phospho-BAD Prevents Its Degradation, Promoting Warburg Glycolysis by Theileria-Transformed Leukocytes.

Authors:  Malak Haidar; Anne Lombès; Frédéric Bouillaud; Eileen J Kennedy; Gordon Langsley
Journal:  ACS Infect Dis       Date:  2017-01-24       Impact factor: 5.084

6.  CaMKII and CaMKIV mediate distinct prosurvival signaling pathways in response to depolarization in neurons.

Authors:  Jinwoong Bok; Qiong Wang; Jie Huang; Steven H Green
Journal:  Mol Cell Neurosci       Date:  2007-06-27       Impact factor: 4.314

7.  Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.

Authors:  Marc Y Fink; Jerry E Chipuk
Journal:  Genes Cancer       Date:  2013-05

8.  Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis.

Authors:  Ning-Bo Liu; Tao Peng; Chao Pan; Yu-Yu Yao; Bo Shen; Jing Leng
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

9.  IGF-1 degradation by mouse mast cell protease 4 promotes cell death and adverse cardiac remodeling days after a myocardial infarction.

Authors:  Thor Tejada; Lin Tan; Rebecca A Torres; John W Calvert; Jonathan P Lambert; Madiha Zaidi; Murtaza Husain; Maria D Berce; Hussain Naib; Gunnar Pejler; Magnus Abrink; Robert M Graham; David J Lefer; Nawazish Naqvi; Ahsan Husain
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

10.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Authors:  Chaoyang Sun; Yong Fang; Jun Yin; Jian Chen; Zhenlin Ju; Dong Zhang; Xiaohua Chen; Christopher P Vellano; Kang Jin Jeong; Patrick Kwok-Shing Ng; Agda Karina B Eterovic; Neil H Bhola; Yiling Lu; Shannon N Westin; Jennifer R Grandis; Shiaw-Yih Lin; Kenneth L Scott; Guang Peng; Joan Brugge; Gordon B Mills
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.